Currently out of the existing stock ratings of Alec Stranahan, 18 are a BUY (54.55%), 8 are a HOLD (24.24%), 7 are a SELL (21.21%).

Alec Stranahan

Work Performance Price Targets & Ratings Chart

Analyst Alec Stranahan, currently employed at BAML, carries an average stock price target met ratio of 61.79% that have a potential upside of 32% achieved within 234 days.

Alec Stranahan’s has documented 66 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on YMAB, Y mAbs Therapeutics at 05-Mar-2025.

Wall Street Analyst Alec Stranahan

Analyst best performing recommendations are on TGTX (TG THERAPEUTICS).
The best stock recommendation documented was for TGTX (TG THERAPEUTICS) at 5/20/2022. The price target of $5 was fulfilled within 4 days with a profit of $0.39 (7.24%) receiving and performance score of 18.09.

Average potential price target upside

NXTC NextCure  KRYS Krystal Biotech NVAX Novavax TGTX TG Therapeutics YMAB Y mAbs Therapeutics DAWN Day One Biopharmaceuticals RVMD Revolution Medicines MGTX MeiraGTx Holdings PLC ERAS Erasca SWTX SpringWorks Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$4

$2.92 (270.37%)

$4

8 months 12 days ago
(02-Aug-2024)

0/7 (0%)

$2.4 (150.00%)

Hold

$16

2 years 5 months 10 days ago
(04-Nov-2022)

0/3 (0%)

$11.08 (225.20%)

Buy

$6

$4.92 (455.56%)

$13

2 years 5 months 11 days ago
(03-Nov-2022)

3/14 (21.43%)

$3.49 (139.04%)

56

Buy

$15

$13.92 (1288.89%)

$19

2 years 7 months 22 days ago
(23-Aug-2022)

1/4 (25%)

$10.56 (237.84%)

185

Buy

$14

$12.92 (1196.30%)

$14

2 years 11 months 8 days ago
(06-May-2022)

0/3 (0%)

$10.2 (268.42%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Alec Stranahan is most bullish on?

Potential upside of $17.88 has been obtained for DAWN (DAY ONE BIOPHARMACEUTICALS)

Which stock is Alec Stranahan is most reserved on?

Potential downside of $3.76 has been obtained for ERAS (ERASCA)

What Year was the first public recommendation made by Alec Stranahan?

On 2018

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?